Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer... Show more
KURA is expected to report earnings to rise 8.39% to -89 cents per share on July 30
Q2'26
Est.
$-0.90
Q1'26
Est.
$-0.83
Q4'25
Missed
by $0.66
Q3'25
Missed
by $0.10
Q2'25
Missed
by $0.34
The last earnings report on May 12 showed earnings per share of -82 cents, meeting the estimate of -82 cents. With 288.47K shares outstanding, the current market capitalization sits at 782.10M.